EMBO Molecular Medicine is an open access journal dedicated to science at the interface between clinical research and the life sciences.EMBO Molecular Medicine has a fair and transparent process (http://embomolmed.embopress.org/about#Transparent_Process) to rapidly publish important science. Anonymous referee reports and editorial correspondence are published alongside manuscripts as Review Process Files in the Transparent Process section online.
《EMBO分子医学》是一本开放获取的期刊，致力于临床研究和生命科学之间的接口科学。《EMBO分子医学》具有公平和透明的流程（http：//embomolmed.embopress.org/about#Transparent_Process），可快速发表重要的科学成果。匿名评审报告和编辑通信与手稿一起作为审查过程文件在透明过程部分在线发布。
Inflammasomes in neuroinflammatory and neurodegenerative diseases
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201810248
The role of the microbiome in NAFLD and NASH
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809302
A dual‐AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock‐out mice
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809396
Cellular, molecular, and clinical mechanisms of action of deep brain stimulation—a systematic review on established indications and outlook on future developments
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809575
Cerebral malaria is associated with differential cytoadherence to brain endothelial cells
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809164
Genetic engineering of hematopoiesis: current stage of clinical translation and future perspectives
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809958
Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809736
ADAM17 selectively activates the IL‐6 trans‐signaling/ERK MAPK axis in KRAS‐addicted lung cancer
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809976
A circRNA signature predicts postoperative recurrence in stage II/III colon cancer
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201810168
Inhibition of proteasome rescues a pathogenic variant of respiratory chain assembly factor COA7
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809561
Lipid droplet‐dependent fatty acid metabolism controls the immune suppressive phenotype of tumor‐associated macrophages
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910698
The novel BET‐CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild‐type prostate cancer
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910659
Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809034
Dyslipidemia in retinal metabolic disorders
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910473
Pyrin dephosphorylation is sufficient to trigger inflammasome activation in familial Mediterranean fever patients
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910547
Epigenetic silencing of SALL2 confers tamoxifen resistance in breast cancer
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910638
Plasma Proteome Profiling to detect and avoid sample‐related biases in biomarker studies
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910427
3,4‐Dimethoxychalcone induces autophagy through activation of the transcription factors TFE3 and TFEB
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910469
Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910924
Control of anterior GRadient 2 (AGR2) dimerization links endoplasmic reticulum proteostasis to inflammation
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201810120
Activation of LXRβ inhibits tumor respiration and is synthetically lethal with Bcl‐xL inhibition
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910769
Requirement for YAP1 signaling in myxoid liposarcoma
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809889
Repurposing the selective estrogen receptor modulator bazedoxifene to suppress gastrointestinal cancer growth
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809539
Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910581
Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809982
CoA‐dependent activation of mitochondrial acyl carrier protein links four neurodegenerative diseases
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910488
Efficacy of simultaneous VEGF‐A/ANG‐2 neutralization in suppressing spontaneous choroidal neovascularization
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201810204
Repurposing the yellow fever vaccine for intratumoral immunotherapy
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910375
Non‐canonical cMet regulation by vimentin mediates Plk1 inhibitor–induced apoptosis
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809960
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910666
Dynorphin‐based “release on demand” gene therapy for drug‐resistant temporal lobe epilepsy
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809963
APOPT1/COA8 assists COX assembly and is oppositely regulated by UPS and ROS
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809582
DNA methylation inhibitor attenuates polyglutamine‐induced neurodegeneration by regulating Hes5
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201708547
Malaria inflammation by xanthine oxidase‐produced reactive oxygen species
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809903
Gender and sex—time to bridge the gap
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910668
The mitochondrial deoxyguanosine kinase is required for cancer cell stemness in lung adenocarcinoma
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910849
Toward personalized TGFβ inhibition for pancreatic cancer
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201911414
Genetically engineered distal airway stem cell transplantation protects mice from pulmonary infection
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201810233
Stop wasting protein—Proteasome inhibition to target diseases linked to mitochondrial import
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910441
Gut microbes, ageing & organ function: a chameleon in modern biology?
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809872
I BET on anti‐FGFR to fight cancer resistance
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201810116
Endoplasmic reticulum stress at the crossroads of progeria and atherosclerosis
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910360
An autocrine ActivinB mechanism drives TGFβ/Activin signaling in Group 3 medulloblastoma
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809830
Funding community collaboration to develop effective therapies for neurofibromatosis type 1 tumors
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201911656
How much does a disrupted mitochondrial network influence neuronal dysfunction?
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201809899
What is normal? Apelin and VEGFA, drivers of tumor vessel abnormality
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910892
Inhibiting TRF1 upstream signaling pathways to target telomeres in cancer cells
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201910845
An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201911209
In search of the next super models
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201911502
Live vaccines—a short‐cut to cancer viro‐immunotherapy
来源期刊：EMBO Molecular MedicineDOI：10.15252/emmm.201911496
